Fifatrol, An Ayurvedic Formulation- A Prospective Multi-Center Observational Study On The Symptoms of Upper Respiratory Tract Infections: DOI: https://doi.org/10.47223/IRJAY.2021.4604

Santosh Kumar  Verma; Abdul Haye; Shubham  Saxena; Mohammad  Junaid; Mukesh Chandra  Sharma

doi:10.47223/IRJAY.2021.4604

Authors

Santosh Kumar Verma Faculty of Pharmaceutical Sciences, Motherhood University, Roorkee, Uttarakhand, India
Abdul Haye Independent Researcher
Shubham Saxena Institute of ManagementTechnology, Ghaziabad, Uttar Pradesh, India
Mohammad Junaid Uttaranchal Ayurvedic College, Dehradun, Uttarakhand, India
Mukesh Chandra Sharma Faculty of Pharmaceutical Sciences, Motherhood University, Roorkee, Uttarakhand, India

DOI:

https://doi.org/10.47223/IRJAY.2021.4604

Keywords:

URTI, Fifatrol, Polyherbal formulation, Post-marketing observational study

Abstract

Background: Upper respiratory tract infections (URTI) is a leading cause of economic burden as it remains among the top 3 diagnosed diseases globally with an estimated annual cost above $22 billion. Available medications to treat URTI and associated symptoms are effective, however, their tolerability remains a challenge for the practitioners. Recently, the use of alternative and complementary therapy has increased for the management of URTI symptoms. Fifatrol is an ayurvedic formulation for the management of URTI and its associated symptoms. However, ts evidence-based data is limited. Therefore, this observational study was aimed to investigate the effects and to assess the safety of Fifatrol on URTI symptoms.

Method: A post-marketing prospective observational study was carried out in the various cities of India. Patients enrolled in the study were presented with the symptoms of URTI in the health care centers and prescribed Fifatrol in twice-daily dose by the practitioners voluntarily. Symptoms of URTI (local, general, total) were collected on a 0–7 Likert scale at three-time points within 1 week (1st day, 4th day, and 7th day), using a questionnaire. Effectiveness was evaluated by examining the reduction in symptoms scores at day 4 and 7 respectively from baseline (day 1)

Results: The mean score of local symptoms was 19.49 (SE: 0.39) on the day1, dropping to 6.82 (SE: 0.14) and 1.84 (SE: 0.04), showing a decrease of 65.0% and 90.55% on the 4th and 7th day respectively (p < 0.001). The mean score of general symptoms reduced from 8.06 (SE: 0.26) on day 1 to 1.62 (SE: 0.5) and 0.8 (SE: 0.03), revealing a reduction of 79.9% and 90.11% on the 4th and 7th day respectively (p < 0.001). The mean total score of symptoms reduced from 28.34 (SE: 0.59) on day 1 to 8.63 (SE: 0.15) and 2.73 (SE: 0.05), indicating a decrease by 69.5% and by 90.36% on the 4th and 7th day respectively (p < 0.001). 1.97% adverse events of mild intensityreported during the observation period.

Conclusions: This observational study has gathered evidence about the effectiveness and safety of Fifatrol on the amelioration of the symptoms of URTI